MARKET WIREYahoo! Finance Canada • 1d ago
Aldeyra Therapeutics, Inc. (ALDX) Options ChainYahoo! Finance Canada report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
Why ALDX Stock surged +4.09% Today — RQD Quant Desk Flash
$0.58 +4.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.58
Aldeyra Therapeutics Inc. (ALDX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $33.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ALDX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ALDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.58 (+4.09% 1D, market cap $33.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 7/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ALDX compare to NNVC and LITS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALDX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NNVC (NanoViricides Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $34.0M) and LITS (Lite Strategy Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $34.1M). Among the 5-stock peer group, ALDX leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ALDX?
▼
Per ALDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001341235), Aldeyra Therapeutics Inc. generated $98.7M in revenue (-41.3% YoY), -$33.8M in net income, and -$33.3M in free cash flow against $72.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.58 (+0.55%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALDX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY ALDX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.6 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.90-18.9% Next Q
47
Q2 (-2Q)Grade D$0.73-12.3% Next Q
44
Q3 (-1Q)Grade D$0.64-9.4% Next Q
42
CurrentGrade D-$0.58-7.6% Hist 90D α
39
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ALDX Turnaround Squeeze
While ALDX currently carries a cautious 39/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.11) and Max Pain ($0.61) forces dealer call-delta covering toward $6.23.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALDX Stock surged +4.09% Today — RQD Quant Desk Flash
Aldeyra Therapeutics Inc. (ALDX) surged +4.09% to $0.58, trading at 2% of its 52-week range ($0.55 – $5.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.55 – $5.93) with RSI-14 at 30.6 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.58 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: ALDX Exhibits 2.96x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live ALDX Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Aldeyra Therapeutics, Inc. Estimates – NASDAQ:ALDXTradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
We Think Aldeyra Therapeutics (NASDAQ:ALDX) Can Afford To Drive Business GrowthSimply Wall St report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Which of Aldeyra Therapeutics (NASDAQ:ALDX), SmartKem (NASDAQ:SMTK), Nexentis Technologies (NASDAQ:NXTS), Powell Max (NASDAQ:PMAX) or Beam Global (NASDAQ:BEEM) Trades Between 50 and 90 Cents in Pre-Market?kalkine.ca report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Weekly Recap: Dispute over reproxalap CRL and $45.1M cash runwayTradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHTradingView • 2d ago
AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowTradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 2d ago
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyTradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 2d ago
PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowTradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 18d ago
12 Health Care Stocks Moving In Friday's After-Market SessionGainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stock
CATALYSTYahoo • 19d ago
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekUltragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALDX)
- ✓Walkthrough of ALDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.20%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.66H $0.66L $0.56C $0.58VOL 896.6K
RES: $1.29SUP: $0.53SMA50: $1.11SMA200: $2.24
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -41.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ALDX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALDX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALDX)
Health Care Rank #490 of 1015
⚔️ NNVC vs ALDX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALDX vs. NNVC, LITS, EDSA, IBO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Aldeyra Therapeutics Inc. (ALDX) ranks #490 by composite RQD confidence (39/100, grade D-) and #786 by equity capitalization ($33.8M). Within this direct 5-issuer industry benchmark cohort, ALDX leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ALDX at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALDX
ACTIVE
Aldeyra Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | +4.09% | $33.8M | Benchmark Subject |
| NNVC NanoViricides Inc. | D- | 37/100 | — | — | -35.0% | +1.50% | $34.0M | /nnvc-vs-aldx → |
| LITS Lite Strategy Inc. | D- | 43/100 | — | — | -18.9% | -13.60% | $34.1M | /lits-vs-aldx → |
| EDSA Edesa Biotech Inc. | E | 29/100 | — | — | -35.0% | -5.06% | $34.7M | /edsa-vs-aldx → |
| IBO Impact BioMedical Inc. | E | 30/100 | — | -30.0% | -27.5% | +5.53% | $32.5M | /ibo-vs-aldx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001341235 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aldeyra Therapeutics Inc. (ALDX) reported GAAP revenue of $98.7M (-41.3% vs. FY2024 revenue of $168.3M , and -17.6% cumulative change since FY2023) , GAAP net income of -$33.8M, operating cash flow of -$33.3M, and free cash flow of -$33.3M (+22.8% YoY). On the balance sheet, ALDX closed FY2025 with $72.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $98.7M | -$33.8M | -$33.3M | -$33.3M | $72.1M | $0 |
| FY2024 (FY) | 2024-12-31 | $168.3M | -$55.9M | -$43.2M | -$43.2M | $104.6M | $15.0M |
| FY2023 (FY) | 2023-12-31 | $119.8M | -$37.5M | -$30.3M | -$30.3M | — | — |
3. ALDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.58 (+4.09% 1D, market cap $33.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 7/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does ALDX compare to NNVC and LITS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALDX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NNVC (NanoViricides Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $34.0M) and LITS (Lite Strategy Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $34.1M). Among the 5-stock peer group, ALDX leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALDX?
Per ALDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001341235), Aldeyra Therapeutics Inc. generated $98.7M in revenue (-41.3% YoY), -$33.8M in net income, and -$33.3M in free cash flow against $72.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALDX trading relative to its 50-day, 200-day, and 52-week technical levels?
ALDX last traded at $0.58 (+4.09% on volume of 906,108 shares), positioning the stock -47.75% below its 50-day simple moving average ($1.11) and -74.11% below its 200-day simple moving average ($2.24). Across its 52-week range of $0.55 to $5.93, ALDX sits at the 0.6% percentile with a 14-day RSI of 30.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.65).
ROARABLE RATING BRIEF • RQD 39/100 (D-)
✓ SEC XBRL & RQD VERIFIED
ALDX — Aldeyra Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Aldeyra Therapeutics Inc. (ALDX) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.58 (+4.09% 1D, market capitalization $33.8M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 0.00x.
2. Business Model, Unit Margins & SEC Financial Trajectory
. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each period shown in the SEC financials, so the company does not appear to generate revenue in the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aldeyra Therapeutics Inc. (ALDX) reported $98.7M in annual revenue (up from $168.3M in FY2024, -41.3% YoY) and -$33.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($119.8M revenue, -$37.5M net income) through FY2025, ALDX scaled operating cash flow to -$33.3M and free cash flow to -$33.3M, backed by $72.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.55 – $5.93 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The graph's liquidity signal shows that, per its regression, ALDX is highly sensitive to net liquidity conditions (2.96x beta), so a tightening in the liquidity measure would be a second-order pressure point.
- Key Question #1: Can ALDX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $98.7M and free cash flow of -$33.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ALDX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ALDX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aldeyra Therapeutics Inc. (ALDX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Aldeyra Therapeutics, Inc. (ALDX) Options Chain Yahoo! Finance Canada report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Aldeyra Therapeutics, Inc. Estimates – NASDAQ:ALDX TradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
We Think Aldeyra Therapeutics (NASDAQ:ALDX) Can Afford To Drive Business Growth Simply Wall St report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Which of Aldeyra Therapeutics (NASDAQ:ALDX), SmartKem (NASDAQ:SMTK), Nexentis Technologies (NASDAQ:NXTS), Powell Max (NASDAQ:PMAX) or Beam Global (NASDAQ:BEEM) Trades Between 50 and 90 Cents in Pre-Market? kalkine.ca report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Weekly Recap: Dispute over reproxalap CRL and $45.1M cash runway TradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH TradingView • 2d ago
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know TradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 2d ago
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why TradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 2d ago
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know TradingView report covering Aldeyra Therapeutics Inc. (ALDX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ALDX Bull vs. Bear Conversation Board — What's Your Call at $0.58?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALDX 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $0.68 (+21.4%)
📌 Pinned Debate Balance sheet posture is the strongest pillar, with reported cash rising to $70.0M and debt falling to $0.0M in FY 2025, per the SEC fi
Balance sheet posture is the strongest pillar, with reported cash rising to $70.0M and debt falling to $0.0M in FY 2025, per the SEC financials and RQD rating.. When you look under the hood at ALDX, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $5.93. My 12M target is $0.68.
EarningsSniper 🐂 BULL
Both sides have a point here — ALDX's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $0.44 (-21.4%)
Spot @ $0.56 The company reports no revenue, a -35% ROIC, and negative FCF in every reported year, with a Macro Tailwind Score of 23/100 and a 2.96x
Careful chasing ALDX at $0.56. The company reports no revenue, a -35% ROIC, and negative FCF in every reported year, with a Macro Tailwind Score of 23/100 and a 2.96x liquidity beta.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.44 on multiple compression.